Nolan M Stubbs,Tyler J Roady,Maximilian P Schwermann et al.
Nolan M Stubbs et al.
Acquired resistance to molecularly targeted therapies remains a formidable challenge in the treatment of cancer, despite significant advancements over the last several decades. We critically evaluate the evolving landscape of resistance mec...
ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC [0.03%]
ZEB2上调调节TAMs向免疫抑制状态极化以促进表皮生长因子受体酪氨酸激酶抑制剂耐药非小细胞肺癌进展
Yunhuan Liu,Yong Yu,Congli Hu et al.
Yunhuan Liu et al.
Aim: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment approach for NSCLC. However, the effectiveness of ICI therapy in patients with EGFR-driven NSCLC, particularly those resistant to EGFR-TKI, has been disappointing. T...
Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer [0.03%]
揭示MAGEA3：一个新的抗贝伐单抗产生耐药的结直肠癌生物标志物
Juncheng Su,Jiahui Wang,Weilin Chen et al.
Juncheng Su et al.
Aim: Bevacizumab has long been a cornerstone in the treatment of colorectal cancer (CRC), serving as a fundamental antiangiogenic therapeutic option. However, a significant proportion of patients exhibit insensitivity to bevacizumab, and no...
Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemness [0.03%]
Ivosidenib通过减少癌症干细胞特性增强卵巢癌对顺铂的敏感性
Mengqing Chen,Lin Huang,Simei Zhao et al.
Mengqing Chen et al.
Aim: Cancer stem cells (CSCs) are pivotal in mediating platinum resistance in ovarian cancer. This study aimed to screen compounds sensitizing CSCs to cisplatin by using a small molecule inhibitor library. Methods: A library of 105 common d...
The genetic architecture of bone metastases: unveiling the role of epigenetic and genetic modifications in drug resistance [0.03%]
骨转移的遗传架构：表观遗传和遗传修饰在耐药中的作用机制不容忽视
Ahmad Dawalibi,Mohamad Bakir,Khalid S Mohammad
Ahmad Dawalibi
Bone metastases represent frequent and severe complications in various cancers, notably impacting prognosis and quality of life. This review article delves into the genetic and epigenetic mechanisms underpinning drug resistance in bone meta...
Jansen Redler,Ariana E Nelson,Christine M Heske
Jansen Redler
A common barrier to the development of effective anticancer agents is the development of drug resistance. This obstacle remains a challenge to successful clinical translation, particularly for targeted agents. Nicotinamide phosphoribosyltra...
Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation [0.03%]
非小细胞肺癌免疫治疗的肿瘤微环境耐药机制及"冷转热"策略研究
Jinglu Yu,Xiaoni Kong,Yu Feng
Jinglu Yu
Non-small cell lung cancer (NSCLC) represents a formidable challenge in oncology due to its molecular heterogeneity and the dynamic suppressive nature of its tumor microenvironment (TME). Despite the transformative impact of immune checkpoi...
Jinghan Hua,Zhe Wang,Xiaoxun Cheng et al.
Jinghan Hua et al.
Acquired drug resistance is a main factor contributing to cancer therapy failure and high cancer mortality, highlighting the necessity to develop novel intervention targets. Circular RNAs (circRNAs), an abundant class of RNA molecules with ...
Exosomal miR-92b-5p regulates N4BP1 to enhance PTEN mono-ubiquitination in doxorubicin-resistant AML [0.03%]
外泌体miR-92b-5p通过调节N4BP1促进PTEN单泛素化在多柔比星耐药急性髓系白血病中的作用
Qianyuan Li,Jie Cheng,Danni Qin et al.
Qianyuan Li et al.
Aim: Doxorubicin, pivotal for acute myeloid leukemia (AML) treatment, often succumbs to resistance, impeding therapeutic success. Although exosomal transfer is linked to chemoresistance, the detailed role of exosomal miRNAs in doxorubicin r...
The epigenetic mechanisms involved in the treatment resistance of glioblastoma [0.03%]
与胶质母细胞瘤治疗抵抗有关的表观遗传机制
Aanya Shahani,Hasan Slika,Ahmad Elbeltagy et al.
Aanya Shahani et al.
Glioblastoma (GBM) is an aggressive malignant brain tumor with almost inevitable recurrence despite multimodal management with surgical resection and radio-chemotherapy. While several genetic, proteomic, cellular, and anatomic factors inter...